Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5284246 | 0.88 | GRIN2B (0.46) | GRM5ITGB3ITGA2BACHEPRMT5 | |
| SCHEMBL3735903 | 0.85 | ITGB3 (0.52) | GRM5ITGB3ITGA2BAOC3 | |
| SCHEMBL4490327 | 0.84 | HRH3 (0.46) | GRM5ITGB3ITGA2BAOC3HRH3 | |
| SCHEMBL4502402 | 0.83 | GRM5 (0.62) | GRM5ITGB3ITGA2BACHEPRMT5 | |
| SCHEMBL29438690 | 0.83 | GRM5 (0.62) | GRM5ITGB3ITGA2BACHEPRMT5 | |
| SCHEMBL7799399 | 0.82 | ITGB3 (0.64) | ITGB3ITGA2B | |
| SCHEMBL3656341 | 0.81 | DRD2 (0.48) | AOC3ACHEHRH3 | |
| SCHEMBL3660375 | 0.80 | HRH3 (0.45) | AOC3ACHEHRH3 | |
| SCHEMBL3652397 | 0.80 | HRH3 (0.45) | AOC3ACHEHRH3 | |
| SCHEMBL7533063 | 0.79 | GRM5 (0.67) | GRM5ACHEHRH3LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| EP-1917241-A2 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007000339-A1 | BICYCLIC DERIVATIVES AS P38 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286775-A1 | Bicyclic Derivatives as P38 Kinase Inhibitors | MAPK1, MAPKAPK2, MAPKAPK3 | GRM5 2566/4885ITGB3 2964/4885ITGA2B 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.